Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BioLineRx (BLRX) Short-term Investments: 2023-2025

Historic Short-term Investments for BioLineRx (BLRX) over the last 2 years, with Jun 2025 value amounting to $21.0 million.

  • BioLineRx's Short-term Investments fell 26.83% to $21.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $21.0 million, marking a year-over-year decrease of 26.83%. This contributed to the annual value of $9.1 million for FY2024, which is 76.44% down from last year.
  • Latest data reveals that BioLineRx reported Short-term Investments of $21.0 million as of Q2 2025, which was up 20.98% from $17.3 million recorded in Q1 2025.
  • Over the past 5 years, BioLineRx's Short-term Investments peaked at $38.7 million during Q4 2023, and registered a low of $9.1 million during Q4 2024.
  • Its 3-year average for Short-term Investments is $22.4 million, with a median of $20.7 million in 2024.
  • Within the past 5 years, the most significant YoY rise in BioLineRx's Short-term Investments was 36.25% (2024), while the steepest drop was 76.44% (2024).
  • Quarterly analysis of 3 years shows BioLineRx's Short-term Investments stood at $38.7 million in 2023, then plummeted by 76.44% to $9.1 million in 2024, then fell by 26.83% to $21.0 million in 2025.
  • Its Short-term Investments stands at $21.0 million for Q2 2025, versus $17.3 million for Q1 2025 and $9.1 million for Q4 2024.